Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Misregulation of BDNF in autism spectrum disorders  

Unusually high levels of the signaling peptide BDNF, or brain-derived neurotrophic factor, have been detected in blood samples from children with autism. Barbara Hempstead of Weill Medical College at Cornell University and her colleagues propose that BDNF may also be over-expressed in the brains of these children, causing neurological defects that lead to the disorder. During brain development, BDNF regulates the birth and differentiation of brain cells, or neurons. Some of BDNF's target cells, such as cortical interneurons, which transmit information between different layers of the brain cortex, have been implicated in autism. BDNF is also a regulator of brain growth, and children with the disorder tend to have abnormally large brains during early development. What's more, MeCP2, a gene in which mutations are known to cause the autism-related Rett syndrome, directly regulates the expression of BDNF. Hempstead and colleagues have preliminary evidence that both neurons and blood platelets regulate BDNF expression using similar mechanisms, suggesting that people who produce high levels in one tissue are also likely to have high levels in the other. Whether increased BDNF signaling disrupts human neural development and causes autism, however, is unknown. To test their hypothesis, the researchers first plan to determine the neurological consequences of expressing too much BDNF in specific regions of the mouse brain known to develop abnormally in autism. Altered mice that modestly overexpress BDNF were analyzed for social interaction–related behaviors and found to have increased interaction time with novel mice placed in the interaction chamber, compared with wild-type littermate controls. There was no difference in baseline anxiety-related behaviors. These findings highlight an unexpected role of BDNF in increasing social interaction, when overexpressed at low to intermediate levels (10-30% above controls). The researchers also aim to test whether BDNF levels in the blood are altered in children with autism. Hempstead and colleagues are analyzing BDNF processing, BDNF levels and BDNF receptors in human platelets and serum from patients and immediate family members. If high BDNF levels do prove to be a cause of the disorder, drugs that block its production or signaling might be an effective treatment for autism. Project Status
ONGOING

2010

Funder Simons Foundation
Fiscal Year Funding $75,000.00
Current Award Period 2008-2011
Project Number 95485
Principal Investigator Hempstead, Barbara
Received ARRA Funding? No
Strategic Plan Question Question 1: When Should I Be Concerned? (Diagnosis)
Subcategory Early Signs and Biomarkers
Strategic Plan Objective Green dot: Objective has greater than or equal to the recommended funding. 1LA. Identify behavioral and biological markers that separately, or in combination, accurately identify, before age 2, one or more subtypes of children at risk for developing ASD, and evaluate whether these risk markers or profiles can improve early identification through heightened developmental monitoring and screening by 2014. IACC Recommended Budget: $33,300,000 over 5 years.
Federal or Private? Private
Institution Weill Cornell Medical College
State/Country New York
Web Link 1 Misregulation of BDNF in autism spectrum disorders (External web link)
Web Link 2 No URL available.
Web Link 3 No URL available.
New! History/Related Projects Misregulation of BDNF in autism spectrum disorders | $150,000.00 | 2009 | 95485